We demonstrated that blocking IFNγ in vivo fully rescues aging-associated intestinal phenotypes and loss of regeneration, elevating IFNγ as a very promising therapeutic target for the treatment of complications of human aging-associated intestinal diseases, including intestinal cancer. This evidence concerns the gene IFNG and intestinal cancer.